# Phase 2 Lupus Erythematosus, Systemic trials: 28 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials in phase 2 for Lupus Erythematosus, Systemic that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Lupus Erythematosus, Systemic trials: 28 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lupus-erythematosus-systemic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 28
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 28, 2026 | NCT07844200 | The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the... | Medical Association for the Study of Cancer Biology and Treatment | Phase 2 | Not yet recruiting | SLE - Systemic Lupus Erythematosus | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844200) |
| August 12, 2026 | NCT07760155 | A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus | Shanghai Escugen Biotechnology Co., Ltd | Phase 2 | Not yet recruiting | Systemic Lupus Erythematosus (SLE) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760155) |
| July 28, 2026 | NCT07729826 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to... | AbelZeta Inc. | Phase 2 | Not yet recruiting | Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729826) |
| July 23, 2026 | NCT07721363 | Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Lupus Nephritis, Membranous Nephropathy | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721363) |
| June 5, 2026 | NCT07630714 | A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to \< 18 Years... | AstraZeneca | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630714) |
| May 20, 2026 | NCT07598396 | A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | Hoffmann-La Roche | Phase 2 | Recruiting | Lupus, Systemic Lupus Erythematosus, Lupus Nephritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598396) |
| May 6, 2026 | NCT07570862 | A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis | Fate Therapeutics | Phase 2 | Recruiting | Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III... | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570862) |
| April 7, 2026 | NCT07515014 | A Study of E6742 in Participants With Systemic Lupus Erythematosus | Eisai Co., Ltd. | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515014) |
| April 3, 2026 | NCT07509892 | A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509892) |
| March 4, 2026 | NCT07447986 | To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus | Hangzhou Sumgen Biotech Co., Ltd. | Phase 2 | Recruiting | Systemic Lupus Erythematosus (SLE) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447986) |
| February 13, 2026 | NCT07409181 | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | Boehringer Ingelheim | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409181) |
| January 14, 2026 | NCT07340463 | The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months... | Nanjing University School of Medicine | Phase 2 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07340463) |
| January 9, 2026 | NCT07328581 | A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis | iCell Gene Therapeutics | Phase 2 | Recruiting | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328581) |
| December 23, 2025 | NCT07299422 | A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07299422) |
| November 6, 2025 | NCT07225543 | 2-HOBA in Systemic Lupus Erythematosus | Vanderbilt University Medical Center | Phase 2 | Recruiting | Systemic Lupus Erthematosus (SLE) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225543) |
| August 24, 2025 | NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | NYU Langone Health | Phase 2 | Recruiting | Rheumatic Disease | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07138898) |
| July 8, 2025 | NCT07053800 | Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) | Autolus Limited | Phase 2 | Recruiting | Lupus Nephritis | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053800) |
| May 23, 2025 | NCT06987565 | Transcutaneous Vagus Nerve Stimulation in SLE | Northwell Health | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06987565) |
| May 14, 2025 | NCT06971913 | Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia | Peking University People's Hospital | Phase 2 | Not yet recruiting | SLE (Systemic Lupus), CMV | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06971913) |
| March 5, 2025 | NCT06859931 | Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Not yet recruiting | Systemic Lupus Erythematosus | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859931) |
| January 27, 2025 | NCT06794008 | BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases | Peking University People's Hospital | Phase 2 | Recruiting | Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis, IgG4-Related... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06794008) |
| January 24, 2025 | NCT06791772 | Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) | Keymed Biosciences Co.Ltd | Phase 2 | Not yet recruiting | Systemic Lupus Erythematosus | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06791772) |
| August 26, 2024 | NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | Amgen | Phase 2 | Recruiting | Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06570798) |
| April 10, 2024 | NCT06356740 | Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus | Hospices Civils de Lyon | Phase 2 | Not yet recruiting | Systemic Lupus Erythematosus | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06356740) |
| June 30, 2022 | NCT05440422 | The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 | Recruiting | Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05440422) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Peking University People's Hospital | 2 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 2 |
| Autolus Limited | 1 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 1 |
| AbelZeta Inc. | 1 |
| Hangzhou Sumgen Biotech Co., Ltd. | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| [Eisai Co., Ltd.](https://specstream.ai/data/clinical-trials/company/eisai-co-ltd) | 1 |
| [Keymed Biosciences Co.Ltd](https://specstream.ai/data/clinical-trials/company/keymed-biosciences-co-ltd) | 1 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1 |
| Hospices Civils de Lyon | 1 |
| Northwell Health | 1 |
| Vanderbilt University Medical Center | 1 |
| Shanghai Escugen Biotechnology Co., Ltd | 1 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| iCell Gene Therapeutics | 1 |
| Medical Association for the Study of Cancer Biology and Treatment | 1 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| State University of New York - Upstate Medical University | 1 |
| Red de Terapia Celular | 1 |
| NYU Langone Health | 1 |
| Nanjing University School of Medicine | 1 |
| [Fate Therapeutics](https://specstream.ai/data/clinical-trials/company/fate-therapeutics) | 1 |
| [Guangdong Hengrui Pharmaceutical Co., Ltd](https://specstream.ai/data/clinical-trials/company/guangdong-hengrui-pharmaceutical-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 11 |
| United States | 10 |
| Brazil | 3 |
| United Kingdom | 3 |
| Australia | 3 |
| France | 3 |
| Spain | 3 |
| Japan | 3 |
| Belgium | 2 |
| Germany | 2 |
| Italy | 2 |
| Portugal | 2 |
| Taiwan | 2 |
| Argentina | 2 |
| Colombia | 2 |
| Mexico | 2 |
| South Africa | 2 |
| Netherlands | 2 |
| Serbia | 2 |
| Greece | 1 |
| Vietnam | 1 |
| United Arab Emirates | 1 |
| South Korea | 1 |
| Chile | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Solar installers in the United States](https://specstream.ai/data/businesses/solar-installers/united-states)
- [Mortgage lenders in the United States](https://specstream.ai/data/businesses/mortgage-lenders/united-states)
- [Furniture wholesalers in the United States](https://specstream.ai/data/businesses/furniture-wholesalers/united-states)
- [Cement suppliers in the United States](https://specstream.ai/data/businesses/cement-suppliers/united-states)
- [Welding companies in the United States](https://specstream.ai/data/businesses/welding-companies/united-states)
- [Psychiatry practices in the United States](https://specstream.ai/data/businesses/psychiatry-practices/united-states)
